Ferring Pharmaceuticals

This phase 3 trial tests a gene therapy called nadofaragene firadenovec against simply watching and waiting in people with intermediate-risk non-muscle invasive bladder cancer. The study will enroll 454 participants who have had a tumor removed. The goal is to see if the gene the…

This phase 3 trial is testing a gene therapy called nadofaragene firadenovec, given directly into the bladder, either alone or combined with chemotherapy or immunotherapy. It is for people with a type of bladder cancer that has not responded to standard BCG therapy. The study aim…

This early-phase trial is testing a gene therapy called nadofaragene firadenovec for people with low-grade upper tract urothelial cancer. The drug is instilled directly into the kidney's renal pelvis. The study aims to see if it is safe and can eliminate the cancer. Twenty adults…

This study compares two bowel-cleansing drinks in 30 children aged 2 to 8 who need a colonoscopy. One group gets CLENPIQ, a ready-to-drink solution, and the other gets MIRALAX, a powder mixed with water. The goal is to see which one cleans the colon better and is safer for kids.

This study will follow 2,500 Chinese women who are prescribed REKOVELLE for the first time during IVF or ICSI treatments. Researchers will track how the drug is used in routine practice, its effectiveness (including live birth rates), and any side effects. The goal is to understa…